DOCSLIB.ORG

Abstracts 97

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abstracts 97 SGC Journal SSC Abstracts 97. Jahreskongress der Schweizerischen Gesellschaft für Chirurgie 8. Gemeinsamer Jahreskongress mit der Schweizerischen Gesellschaft für Thorax-, Herz- und Gefässchirurgie Interlaken, 26.-28. Mai 2010 97e congrès annuel de la Société Suisse de Chirurgie 8e congrès annuel en commun avec la Société Suisse de Chirurgie Thoracique et Cardio-Vasculaire swiss knife 2010; 7: special edition Selektiver vollsynthetischer Faktor-Xa Inhibitor1 ESC Guidelines NSTE-ACS-2007 Grad 1A 2 8 th ACCP Guidelines 2008 in allen Indikationen Zur Behandlung des ACS (UA/NSTEMI + STEMI) 2.5 mg 1× täglich, unabhängig vom Körpergewicht 3 Zur Prophylaxe von venösen thromboembolischen Ereignissen 2.5 mg 1× täglich, unabhängig vom Körpergewicht Zur Behandlung der tiefen Venenthrombose und der akuten Lungenembolie 7.5 mg 1× täglich, für die grosse Mehrheit der Patienten (50–100 kg KG) Referenzen: 1. Arzneimittelkompendium der Schweiz 2008, www.kompendium.ch. 2. Bassand J-P, et al for the Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007; 28:1598-1660. 3. J Hirsh, G Guyatt, Antithrombotic and Thrombolytic Therapy, 8th Ed: ACCP Guidelines. Chest. 2008;133 (Suppl 6):67S-968S. ARIXTRA®. W: Fondaparinux natrium I: Prophylaxe venöser thromboembolischer Ereignisse (VTE) bei grösseren orthopädischen Eingriffen und in der Bauchchirurgie. Prophylaxe von VTE bei immobilisierten Patienten mit hohem VTE Risiko, die wegen einer akuten Erkrankung wie einer Herzinsuffi zienz, akuter respiratorischer Insuffi zienz, akuter Infektion oder Entzündung behandelt werden. Behandlung der tiefen Venenthrombose (TVT) und Behandlung der akuten Lungenembolie (LE) wenn keine Lysebehandlung oder Embolektomie durchgeführt wird, in Kombination mit einem Coumarinderivat. Behandlung des akuten Koronarsyndroms mit instabiler Angina pectoris oder Myokardinfarkt ohne ST-Hebung (UA/NSTEMI). Behandlung des akuten Myokardinfarkts mit ST-Hebung (STEMI). D: Prophylaxe in der Chirurgie: postoperativ 1x täglich 2.5 mg subkutan, mindestens 6 Stunden nach Abschluss des Eingriffs und nach Überprüfung der lokalen Hämostase. Behandlung solange fortführen, bis kein Thrombo- embolie-Risiko mehr besteht, mindestens aber über 7 ± 2 Tage nach dem chirurgischen Eingriff. Bei Risikopatienten Behandlung um 24 Tage verlängern. Prophylaxe in der Inneren Medizin: immobilisierte Patienten erhalten 1x täglich 2.5 mg subkutan für eine Behandlungsdauer von 6–14 Tagen. Behandlung der TVT sowie der LE mit 7.5 mg 1x täglich subkutan (50–100 kg KG). Unter 50 kg KG beträgt die empfohlene Dosis 5 mg, über 100 kg KG 10 mg. Die Behandlung ist während mindestens 5 Tagen fortzusetzen, bis eine adäquate orale Antikoagulation erreicht ist. Behandlung UA/NSTEMI: 2.5 mg s.c. 1x täglich. Behandlung STEMI: 2.5 mg 1x täglich. Die erste Dosis von Arixtra wird als i.v. Bolusinjektion oder Injektion über 2 Minuten, alle folgenden Dosen s.c. gegeben. KI: akute schwere Blutungen, be- kannte Überempfi ndlichkeit gegenüber Fondaparinux, akute bakterielle Endokarditis, schwere Niereninsuffi zienz (ClKreat < 20 ml/min). VM: Bei Spinal-Epidural Anästhesie oder einer Lumbalpunktion, können spinale oder epidurale Hämatome nicht ausgeschlossen werden. Bei STEMI-Patienten wird die Anwendung vor und während einer primären PCI nicht empfohlen. IA: Die Behandlung mit Medikamenten, welche das Blutungsrisiko erhöhen können, muss abgesetzt werden. UW: Häufi g: Anämie, Blutungen, Thrombozytopenie, Purpura, Hypokaliämie, Schlafl osigkeit, Anomalien der Leberwerte, Makulo- papulärer Rash, bullöse Eruption, Harnwegsinfektionen, Ödeme. Gelegentlich: Thrombozytose, Schwindel, Benommenheit, Kopfschmerzen, Hypotonie, Übelkeit, Erbrechen, Bauchschmerzen, Dyspepsie, Gastritis, Obstipation, Diarrhö, erythemischer Rash, Rash, Pruritus, Reaktionen an der Einstichstelle, Fieber, periphere Ödeme, Wundsekretion. Selten: intrakranielle/intrazerebrale und retroperitoneale Blutungen, allergische Reaktion. Packungen: Fertigspritzen mit automatischem Sicherheitssystem zu 1.5 mg/0.3 ml (7*), 2.5 mg/0.5 ml (2*, 10*, 10x10), 5 mg/0.4 ml (2*, 10*, 5x10), 7.5 mg/0.6 ml (2*, 10*, 5x10), 10 mg/ 0.8 ml (2*, 10*, 5x10). Verkaufskategorie: B. Für weitere Informationen, bitte Arzneimittel-Kompendium der Schweiz konsultieren. www.kompendium.ch * kassenzulässig GlaxoSmithKline AG, Talstrasse 3–5, 3053 Münchenbuchsee, www.glaxosmithkline.ch Editorial Der Jahreskongress der Le congrès annuel des sociétés spé- Chirurgischen Fachgesellschaften cialisées en chirurgie Liebe Kolleginnen und Kollegen Chères/Chers collègues Wir freuen uns, Ihnen den Abstract-Band von swiss knife für unseren Jahres- Nous sommes heureux de vous présenter la brochure des résumés de notre kongress 2010 in Interlaken präsentieren zu dürfen. Weit über 400 Abstracts congrès annuel 2010 swiss knife à Interlaken. Plus de 400 résumés qui tou- aus allen Schwerpunktgesellschaften und assoziierten Gruppen der SGC be- chent toutes les sociétés de formation approfondie et groupes associés à la reichern diesen Kongress. Es ist uns ein grosses Anliegen, den Autoren für SSC enrichissent ce congrès. Il nous tient particulièrement à cœur de remer- ihre wertvollen Beiträge zu danken. Der ganze Kongress basiert auf diesen cier les auteurs pour leurs précieuses contributions: c’est sur elles que repose Beiträgen und auf der Mitarbeit der Vertreterinnen und Vertreter der Schwer- l’intégralité du congrès, tout comme sur la collaboration des représentantes punktgesellschaften. Wir sind stolz auf diese hoch qualifizierte Auswahl. et représentants des sociétés de formation approfondie. Nous sommes fiers de ce choix hautement qualifié. Am Kongress selbst haben wir für Sie diverse Highlights vorbereitet und wir freuen uns, jeden von Ihnen einzeln in Interlaken begrüssen zu dürfen. Beson- Ce congrès vous réserve plusieurs temps forts, et nous nous réjouissons ders hervorheben möchten wir die Eröffnungsfreier, die am Mittwochnach- d’accueillir personnellement chacun d’entre vous à Interlaken. Nous souhai- mittag stattfindet und mit einem Festvortrag mit dem Thema „Von Internisten tons tout particulièrement attirer votre attention sur la fête d’inauguration qui und Chirurgen“ von Prof. Oelz bereichert wird. Ein weiteres Highlight ist die se tiendra mercredi après-midi et qu’enrichira l’exposé officiel du Prof. Oelz, Lecture „The presidents’ special interest“: Der theoretische Physiker Ben avec le sujet «Des internistes et des chirurgiens». La lecture de «The presi- Moore wird unter dem vielversprechenden Titel „Life, the universe and our dents special interest» formera un autre temps fort, à l’occasion duquel le ultimate fate“ über unsere Zukunft sprechen. Dies muss die Chirurgen und physicien théorique Ben Moore tiendra un exposé au titre prometteur «Life, Anästhesisten doch einfach interessieren. the universe and our ultimate fate», qui ne manquera pas d’intéresser chirur- giens et anesthésistes. Am dritten Tag werden wir zusammen mit den Anästhesisten ein sehr attrak- tives wissenschaftliches Programm bestreiten und vor diesem wissenschaft- Le troisième jour, nous aurons droit, avec les anesthésistes, à un programme lichen Teil wird die British Journal of Surgery Lecture stattfinden. Dieses Jahr scientifique particulièrement captivant. La lecture du British Journal of Sur- ist es uns gelungen, mit Peter Sloterdjik, einen philosophischen Redner von gery aura lieu avant ce volet scientifique. Avec Peter Sloterdjik, nous avons Höchstklasse zu finden. Abgesehen von diesen wissenschaftlichen High- trouvé cette année un orateur et philosophe de premier ordre. En plus de lights ist eine Industrieausstellung vorbereitet, die ebenfalls interessante Neu- ces temps forts scientifiques, nous avons préparé une exposition industrielle igkeiten enthält. Und am Chirurgenabend soll auch für den gemütlichen Teil qui recèle également des nouveautés intéressantes. La soirée des chirurgiens gesorgt sein. constituera, en outre, la partie conviviale. Wir freuen uns, Sie alle in Interlaken persönlich begrüssen zu dürfen und be- Nous nous réjouissons de vous souhaiter personnellement la bienvenue et danken uns bei allen, die zum Gelingen des Kongresses beitragen – insbe- remercions tous ceux qui ont contribué à la réussite de ce congrès, en parti- sondere auch den Sponsoren aus der gesamten Industrie. culier les sponsors de toutes les branches industrielles. Bis bald in Interlaken, A bientôt à Interlaken Prof. Dr. med. Othmar Schöb Prof. Dr. med. Peter Stierli Prof. Dr. med. Othmar Schöb Prof. Dr. med. Peter Stierli Präsident SGC Präsident SGTHGC Président SSC Président SSCTCV 2011 2011 98. Jahreskongress der Schweizerischen Gesellschaft für Chirurgie 98e congrès annuel de la Société Suisse de Chirurgie 9. gemeinsamer Jahreskongress mit der Schweizerischen Gesellschaft für 9e congrès annuel en commun avec la Société Suisse de Chirurgie Tho- Thorax-, Herz- und Gefässchirurgie racique et Cardio-Vasculaire Genf, 25.-27. Mai 2011 Genève, 25–27 mai 2011 Abstract-Deadline: 17. Januar 2011 Abstract Deadline: 17. janvier 2011 swiss knife 2010; 7: special edition 3 HARMONIC FOCUS Long – noch gewebeschonender, noch ergonomischer, noch präziser. Ab sofort erhältlich Für offene Verfahren im oberen Gastrointestinaltrakt sowie in der Kolorektalchirurgie Johnson & Johnson AG, Ethicon Endo-Surgery Schweiz, Rotzenbühlstrasse 55, 8957 Spreitenbach, Tel. +41 56 417 33 33, Fax +41 56 417 35 24 Content Abstracts Session Topic Page 02 Visceral Surgery – Cholecystitis & Appendicitis
Load more

Recommended publications
  • Immune Evasion by Herpes Simplex Viruses
    Chapter 5 Immune Evasion by Herpes Simplex Viruses Angello R. Retamal-Díaz, Eduardo Tognarelli, Alexis M. Kalergis, Susan M. Bueno and Pablo A. González Additional information is available at the end of the chapter http://dx.doi.org/10.5772/64128 Abstract Infection with herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) is extremely frequent in the human population, as well as recurrent reactivations due to lifelong infection. Infection and persistence of HSVs within healthy individuals likely results as a consequence of numerous molecular determinants evolved by these pathogens to escape both immediate and long-term host antiviral mechanisms. Indeed, HSVs harbor an arsenal of proteins that confer them stealth by negatively modulating immune function. Consequently, these viruses perpetuate within the host, altogether silently shedding onto other individuals. In this chapter, we discuss HSV determinants that interfere with cellular antiviral factors, as well as viral determinants that hamper innate and adaptive immune components intended to control such microbes. The identifica‐ tion of HSV evasion molecules that modulate the immune system, as well as the understanding of their mechanisms of action, should facilitate the design of novel prophylactic and therapeutic strategies to overcome infection and disease elicited by these viruses. This chapter is intended to provide an overview of the evasion mecha‐ nisms evolved by herpes simplex viruses to escape numerous host antiviral mediators. Keywords: immune evasion, innate immunity, adaptive immunity, antiviral response 1. Introduction Herpes simplex viruses (HSVs, HSV-1 and HSV-2) are extremely prevalent in the human population with virtually half of the world inhabitants infected with HSV-1 [1] and nearly 500 million with HSV-2 [2].
    [Show full text]
  • The Impact of HSV-1 Infection, SOCS1 Peptide, And
    Wright State University CORE Scholar Browse all Theses and Dissertations Theses and Dissertations 2016 The Impact of HSV-1 Infection, SOCS1 Peptide, and SOCS3 Peptide Mimetic on Cell Viability, Morphology, and Cytoskeleton Proteins of Unpolarized and Cytokine-Polarized M1 RAW 264.7 Murine Macrophages Mubarak Almutairi Wright State University Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all Part of the Immunology and Infectious Disease Commons, and the Microbiology Commons Repository Citation Almutairi, Mubarak, "The Impact of HSV-1 Infection, SOCS1 Peptide, and SOCS3 Peptide Mimetic on Cell Viability, Morphology, and Cytoskeleton Proteins of Unpolarized and Cytokine-Polarized M1 RAW 264.7 Murine Macrophages" (2016). Browse all Theses and Dissertations. 1513. https://corescholar.libraries.wright.edu/etd_all/1513 This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE Scholar. For more information, please contact [email protected]. The Impact of HSV-1 Infection, SOCS1 peptide, and SOCS3 peptide mimetic on Cell Viability, Morphology, and Cytoskeleton Proteins of Unpolarized and Cytokine-Polarized M1 RAW 264.7 Murine Macrophages A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science. By Mubarak Huraysan Almutairi B.S., King Saud University, 2010 2016 Wright State University WRIGHT STATE UNIVERSITY THE GRADUATE SCHOOL April 25, 2016 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY Mubarak Huraysan Almutairi ENTITLED The Impact of HSV-1 Infection, SOCS1 peptide, and SOCS3 peptide mimetic on Cell Viability, Morphology, and Cytoskeleton Proteins of Unpolarized and Cytokine- Polarized M1 RAW 264.7 Murine Macrophages BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science.
    [Show full text]
  • A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures
    viruses Communication A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures Ryan P. Bennett 1,† , Courtney L. Finch 2,† , Elena N. Postnikova 2 , Ryan A. Stewart 1, Yingyun Cai 2 , Shuiqing Yu 2 , Janie Liang 2, Julie Dyall 2 , Jason D. Salter 1 , Harold C. Smith 1,* and Jens H. Kuhn 2,* 1 OyaGen, Inc., 77 Ridgeland Road, Rochester, NY 14623, USA; [email protected] (R.P.B.); [email protected] (R.A.S.); [email protected] (J.D.S.) 2 NIH/NIAID/DCR/Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA; courtney.fi[email protected] (C.L.F.); [email protected] (E.N.P.); [email protected] (Y.C.); [email protected] (S.Y.); [email protected] (J.L.); [email protected] (J.D.) * Correspondence: [email protected] (H.C.S.); [email protected] (J.H.K.); Tel.: +1-585-697-4351 (H.C.S.); +1-301-631-7245 (J.H.K.) † These authors contributed equally to this work. Abstract: Filoviruses, such as Ebola virus and Marburg virus, are of significant human health concern. From 2013 to 2016, Ebola virus caused 11,323 fatalities in Western Africa. Since 2018, two Ebola virus disease outbreaks in the Democratic Republic of the Congo resulted in 2354 fatalities. Although there is progress in medical countermeasure (MCM) development (in particular, vaccines and antibody- based therapeutics), the need for efficacious small-molecule therapeutics remains unmet. Here we describe a novel high-throughput screening assay to identify inhibitors of Ebola virus VP40 matrix protein association with viral particle assembly sites on the interior of the host cell plasma membrane.
    [Show full text]
  • Download Special Issue
    Advances in Virology Virus Immune Evasion: New Mechanism and Implications in Disease Outcome Guest Editors: Rika Draenert, John Frater, and Julia G. Prado Virus Immune Evasion: New Mechanism and Implications in Disease Outcome Advances in Virology Virus Immune Evasion: New Mechanism and Implications in Disease Outcome Guest Editors: Rika Draenert, John Frater, and Julia G. Prado Copyright © 2012 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Advances in Virology.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is prop- erly cited. Editorial Board AmiyaK.Banerjee,USA Alain Kohl, UK Jean Rommelaere, Germany Jay C. Brown, USA Young-Min Lee, USA Peter Rottier, The Netherlands Michael Bukrinsky, USA Blanca Lupiani, USA Dominique Schols, Germany Bruno Canard, France Shinji Makino, USA Robert Snoeck, Belgium Jaquelin Dudley, USA Masao Matsuoka, Japan Edward Stephens, USA Eric O. Freed, USA Trudy Morrison, USA H. J. Thiel, Germany Robert C. Gallo, USA A. Osterhaus, The Netherlands Subhash Verma, USA Gary S. Hayward, USA George N. Pavlakis, USA WilliamS.M.Wold,USA William Irving, UK Finn S. Pedersen, Denmark Frank Kirchhoff,Germany Stefan Pohlmann,¨ Germany Contents Virus Immune Evasion: New Mechanism and Implications in Disease Outcome, Rika Draenert, John Frater, and Julia G. Prado Volume 2012, Article ID 490549, 1 page Viral Infection: An Evolving
    [Show full text]
  • Bench to Bedside Immunotherapy of Cancers Nima Rezaei Editor Second Edition
    Cancer Immunology Bench to Bedside Immunotherapy of Cancers Nima Rezaei Editor Second Edition 123 Nima Rezaei Editor Cancer Immunology Bench to Bedside Immunotherapy of Cancers Second Edition Editor Nima Rezaei Research Center for Immunodeficiencies Children’s Medical Center Tehran University of Medical Sciences Tehran Iran Department of Immunology School of Medicine Tehran University of Medical Sciences Tehran Iran Network of Immunity in Infection Malignancy and Autoimmunity (NIIMA) Universal Scientific Education and Research Network (USERN) Tehran Iran ISBN 978-3-030-50286-7 ISBN 978-3-030-50287-4 (eBook) https://doi.org/10.1007/978-3-030-50287-4 © Springer Nature Switzerland AG 2015, 2021 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made.
    [Show full text]
  • Analyse Der Atpase-Aktivität Des Rekonstituierten Antigenpeptid-Transporters TAP
    Analyse der ATPase-Aktivität des rekonstituierten Antigenpeptid-Transporters TAP Dissertation zur Erlangung des Doktorgrades der Naturwissenschaften vorgelegt beim Fachbereich Chemische und Pharmazeutische Wissenschaften (FB 14) der Johann Wolfgang Goethe-Universität in Frankfurt am Main von Stanislav Gorbulev aus Moskau Frankfurt am Main 2004 Vom Fachbereich Chemische und Pharmazeutische Wissenschaften (FB 14) der Johann Wolfgang Goethe-Universität als Dissertation angenommen Dekan: Prof. H. Schwalbe Gutachter: Prof. R. Tampé, Prof. B. Ludwig Datum der Disputation: 22. Dezember 2004 Analyse der ATPase-Aktivität des rekonstituierten Antigenpeptid-Transporters TAP Angefertigt an der Johann Wolfgang Goethe-Universität Frankfurt am Main Die vorliegende Arbeit wurde an der Philipps-Universität Marburg am Lehrstuhl für Physiologische Chemie II und am Institut für Biochemie an der Johann Wolfgang Goethe-Universität Frankfurt am Main unter der Anleitung von Prof. Dr. Robert Tampé angefertigt. Teile der vorgelegten Arbeit sind veröffentlicht in: Gorbulev, S., Abele, R.& Tampé, R. (2001) Allosteric crosstalk between peptide- binding, transport, and ATP hydrolysis of the ABC transporter TAP. Proc. Natl. Acad. Sci. U. S. A., 98, 3732-3737. Kyritsis, C., Gorbulev, S., Hutschenreiter, S., Pawlitschko, K., Abele, R. & Tampé, R. (2001) Molecular Mechanism and Structural Aspects of TAP Inhibition by the cytomegalievirus Protein US6. J. Biol. Chem. 276, 48031-48039. Danksagung Ich bedanke mich zunächst bei Prof. Dr. Robert Tampé für die interessante Themenstellung, intensive Betreuung der vorliegenden Arbeit und die Möglichkeit, diese in seinem Institut durchführen zu können. Bei Prof. Dr. Bernd Ludwig bedanke ich mich für die Übernahme des Korreferates. Ganz besonders danke ich all den Kollegen, die die Zeit der Promotion zu einer wunderbaren Zeit gemacht haben: Stephan Uebel, Lars Neumann, Stefan Ammer, Kurt Pawlitschko, Min Chen, Ulf Rädler, Nils Hanekop, Carsten Horn, Silke Hutschenreiter, Carmen Graf, Matthias Hofacker, Susanne Heintke, Suman Lata, Martynas Gavutis, Dr.
    [Show full text]
  • BK Polyomavirus Evades Innate Immune Sensing by Disrupting the Mitochondrial
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.19.994988; this version posted March 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. BK polyomavirus evades innate immune sensing by disrupting the mitochondrial network and membrane potential and promotes mitophagy Julia Manzetti1†, Fabian H. Weissbach1, Fabrice E. Graf1, Gunhild Unterstab1‡, Marion Wernli1, Helmut Hopfer2, Cinthia B. Drachenberg3, Christine Hanssen Rinaldo4,5, Hans H. Hirsch1,6,7,* Affiliations 1 Transplantation & Clinical Virology, Department Biomedicine (Haus Petersplatz), University of Basel, Basel, Switzerland. 2 Institute for Pathology, University Hospital Basel, Basel, Switzerland. 3 Departments of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA. 4 Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway. 5 Metabolic and Renal Research Group, UiT The Arctic University of Norway, Tromsø, Norway. 6 Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland. 7 Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland. †present address: Oncology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland ‡present address: Immunobiology, Department Biomedicine, University of Basel, Basel, Switzerland *Correspondence Hans H. Hirsch, MD, MSc Transplantation & Clinical Virology, 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.03.19.994988;
    [Show full text]
  • OS Obisesan Orcid.Org 0000-0003-2165-3636
    Molecular Prevalence of HSV1/2 from HIV-1 Positive and HIV-1 Negative sera collected from North-West and KwaZulu-Natal Provinces OS Obisesan Orcid.org 0000-0003-2165-3636 Dissertation submitted in fulfilment of the requirements for the degree Master of Science in Biology (Medical Virology) at the North West University Supervisor: Prof. NP Sithebe Co-Supervisor: Dr. L Makhado Examination: November 2018 Student number: 27521680 Table of Contents Table of Contents ..................................................................................................................................... i LIST OF FIGURES ...................................................................................................................................... v LIST OF TABLES ...................................................................................................................................... vii DECLARATION ........................................................................................................................................ ix ACKNOWLEDGEMENTS .......................................................................................................................... xi ABSTRACT .............................................................................................................................................. xii LIST OF ABBREVIATIONS .......................................................................................................................xiv DEFINITIONS OF TERMS ........................................................................................................................xvi
    [Show full text]
  • Simplex Virus Immune Evasion Dendritic Cells As a Target For
    CD1 Antigen Presentation by Human Dendritic Cells as a Target for Herpes Simplex Virus Immune Evasion This information is current as Martin J. Raftery, Florian Winau, Stefan H. E. Kaufmann, of September 26, 2021. Ulrich E. Schaible and Günther Schönrich J Immunol 2006; 177:6207-6214; ; doi: 10.4049/jimmunol.177.9.6207 http://www.jimmunol.org/content/177/9/6207 Downloaded from References This article cites 79 articles, 38 of which you can access for free at: http://www.jimmunol.org/content/177/9/6207.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CD1 Antigen Presentation by Human Dendritic Cells as a Target for Herpes Simplex Virus Immune Evasion1 Martin J. Raftery,* Florian Winau,† Stefan H. E. Kaufmann,† Ulrich E. Schaible,† and Gu¨nther Scho¨nrich2* In contrast to MHC molecules, which present peptides, the CD1 molecules have been discovered to present lipid Ags to T cells.
    [Show full text]
  • The Neuroprotective Effect of the Heat Shock Proteins
    THE NEUROPROTECTIVE EFFECT OF THE HEAT SHOCK PROTEINS MARCUS JAMES DERMOT WAGSTAFF A thesis submitted to the University of London for the degree of Doctor of Philosophy. October 1997. Department of Molecular Pathology Windeyer Institute of Medical Sciences Division of Pathology University College London Medical School London ProQuest Number: 10105625 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10105625 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract The work presented in this thesis investigates the protective effects of the heat shock proteins in neurons against the cytopathic effects of exogenous stress. The heat shock proteins (hsps) are a group of proteins that are overexpressed in cells in response to temperatures above the cells optimum growth tenq)erature. Cerebral ischaemia in vivo increases the levels of heat shock proteins and their mRNAs. A brief ‘sub-lethal’ ischaemic insult prior to a ‘lethal’ ischaemic stress has two effects. Firstly, hsps are overexpressed, and secondly, the extent of neuronal damage is significantly reduced as con^ared with models that undergo the single ‘lethal’ ischaemic insult.
    [Show full text]
  • Oncolytic Herpes Simplex Virus and Temozolomide Synergistically Inhibit Breast Cancer Cell Tumorigenesis in Vitro and in Vivo
    ONCOLOGY LETTERS 21: 99, 2021 Oncolytic herpes simplex virus and temozolomide synergistically inhibit breast cancer cell tumorigenesis in vitro and in vivo JINGJING FAN1*, HUA JIANG2*, LIN CHENG2, BINLIN MA1 and RENBIN LIU2 1Department of Breast and Neck Surgery, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, Xinjiang 830011; 2Breast Cancer Center, Department of Breast and Thyroid Surgery, The Third Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510630, P.R. China Received October 14, 2019; Accepted September 23, 2020 DOI: 10.3892/ol.2020.12360 Abstract. The oncolytic herpes simplex virus (HSV) G47Δ TMZ alone. Synergy between G47Δ and TMZ was at least can selectively eliminate glioblastoma cells via viral replica‑ partially mediated via TMZ‑induced acceleration of G47Δ tion and temozolomide (TMZ) has been clinically used to replication, and such a synergy in breast cancer cells in vitro treat glioblastoma. However, the combined effect of G47Δ and in vivo provides novel insight into the future development and TMZ on cancer cells, particularly on breast cancer of a therapeutic strategy against breast cancer. cells, remains largely unknown. The objective of the present study was to investigate the role and underlying mechanism Introduction of G47Δ and TMZ, in combination, in breast cancer cell tumorigenesis. The human breast cancer cell lines SK‑BR‑3 Breast cancer is the most common life‑threatening cancer in and MDA‑MB‑468 were treated with G47Δ and TMZ indi‑ women globally, with an annual rate of new cases reaching vidually or in combination. Cell viability, flow cytometry, 126/100,000 women and a death rate of ~30% (1).
    [Show full text]
  • Minireview Virus Infections: Escape, Resistance, and Counterattack
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Immunity, Vol. 15, 867–870, December, 2001, Copyright 2001 by Cell Press Virus Infections: Escape, Minireview Resistance, and Counterattack Xiao-Ning Xu, Gavin R. Screaton, chains from the ER to the cytosol (US2 and 11), or retain and Andrew J. McMichael class I molecules in the ER (US3). In another example, MRC Human Immunology Unit CTL recognition is inhibited by downregulation of MHC Weatherall Institute of Molecular Medicine class I expression on the surface of infected cells by John Radcliffe Hospital human immunodeficiency virus (HIV) nef protein (Collins Headington, Oxford OX3 9DS et al., 1998). Nef can reroute the MHC class I molecules United Kingdom to clathrin-coated pits for endosomal degradation, which is dependent on a sequence motif in the cyto- plasmic tail of the classical class I molecules (HLA-A and HLA-B locus) (Le Gall et al., 1998). On the other Many viruses establish life-long infections in their nat- hand, HLA-C and HLA-E molecules that are able to bind ural host with few if any clinical manifestations. The to inhibitory receptors of natural killer (NK) cells do not relationship between virus and host is a dynamic pro- contain this motif and are not downregulated by Nef cess in which the virus has evolved the means to coex- (Cohen et al., 1999). Thus, HIV-1 has evolved a strategy ist by reducing its visibility, while the host immune aimed at selective elimination of class I expression that system attempts to suppress and eliminate infection avoids downregulation of those class I molecules which without damage to itself.
    [Show full text]